Skip to content
Oruka Therapeutics, Inc

Polen Capital Management Oruka Therapeutics, Inc transactions over time

ORKA

Oruka Therapeutics, Inc historical holders

total: 2

Transactions details

Total transactions:
1
New positions:
1
Held since:
2026 Q3
Held for:
1 quarter
Latest activity:
2026 Q3
Polen Capital Management has been an institutional investor in Oruka Therapeutics, Inc (ORKA) since 2026 Q3. According to 2026 Q3 report, Polen Capital Management holds 36,274 shares with a market value of roughly $3.02M representing 0.03% of their equity portfolio. The fund/company first acquired ORKA in 2026 Q3, initially purchasing 36,274 shares.

Does Polen Capital Management still hold ORKA?

Yes, Polen Capital Management continues to hold Oruka Therapeutics, Inc (ORKA). According to their 2026 Q3 report, they maintain a position of 36,274 shares valued at approximately $3.02M, representing 0.03% of their equity portfolio.

When did Polen Capital Management first invest in ORKA?

Polen Capital Management first invested in Oruka Therapeutics, Inc (ORKA) in 2026 Q3 at the reported quarter-end price of $83.29 per share, acquiring 36,274 shares in their initial purchase.

What is Polen Capital Management's average cost basis for ORKA?

Based on historical transaction data, Polen Capital Management's estimated cost basis for Oruka Therapeutics, Inc (ORKA) is approximately $83.29 per share. This represents their average reported price* across all buy transactions.

Estimated cost basis*

Weighted AVG buy price:
$83.29

ORKA transactions history by Polen Capital Management

1 result
Period % of
portfolio
Shares
held after*
Reported
price*
Value* % (shares)
of activity
% change
to portfolio
2026 Q3
0.03%
36,274
$83.29
$3,021,261
new
+0.03%
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.